| Literature DB >> 30953029 |
Xiao-Peng Tian1, Wei-Juan Huang2, Hui-Qiang Huang3, Yan-Hui Liu4, Liang Wang5, Xi Zhang6, Tong-Yu Lin4, Hui-Lan Rao7, Mei Li7, Fang Liu8, Fen Zhang5, Li-Ye Zhong9, Li Liang10, Xiao-Liang Lan11, Juan Li12, Bing Liao13, Zhi-Hua Li14, Qiong-Lan Tang14, Qiong Liang15, Chun-Kui Shao15, Qiong-Li Zhai16, Run-Fen Cheng16, Qi Sun17, Kun Ru16, Xia Gu18, Xi-Na Lin18, Kun Yi19, Yue-Rong Shuang20, Xiao-Dong Chen21, Wei Dong22, Wei Sang23, Cai Sun24, Hui Liu24, Zhi-Gang Zhu25, Jun Rao6, Qiao-Nan Guo26, Ying Zhou27, Xiang-Ling Meng28, Yong Zhu29, Chang-Lu Hu30, Yi-Rong Jiang31, Ying Zhang32, Hong-Yi Gao33, Wen-Jun He34, Zhong-Jun Xia35, Cheng-Lei Wu1, Mei-Yin Zhang1, Hui-Yun Wang1, Dan Xie36, Qing-Qing Cai37,38.
Abstract
New prognostic factors are needed to establish indications for haematopoietic stem cell transplantation (HSCT) in first complete remission (CR1) for T-cell lymphoblastic lymphoma (T-LBL) patients. We used microarray to compare T-LBL tissue samples (n = 75) and fetal thymus tissues (n = 20), and identified 35 differentially expressed miRNAs. Using 107 subjects as the training group, we developed a five-miRNA-based classifier to predict patient survival with LASSO Cox regression: lower risk was associated with better prognosis (disease-free survival (DFS): hazard ratio (HR) 4.548, 95% CI 2.433-8.499, p < 0.001; overall survival (OS): HR 5.030, 95% CI 2.407-10.513, p < 0.001). This classifier displayed good performance in the internal testing set (n = 106) and the independent external set (n = 304). High risk was associated with more favorable response to HSCT (DFS: HR 1.675, 95% CI 1.127-2.488, p = 0.011; OS: HR 1.602, 95% CI 1.055-2.433, p = 0.027). When combined with ECOG-PS and/or NOTCH1/FBXW7 status, this classifier had even better prognostic performance in patients receiving HSCT (DFS: HR 2.088, 95% CI 1.290-3.379, p = 0.003; OS: HR 1.996, 95% CI 1.203-3.311, p = 0.007). The five-miRNA classifier may be a useful prognostic biomarker for T-LBL adults, and could identify subjects who could benefit from HSCT.Entities:
Year: 2019 PMID: 30953029 DOI: 10.1038/s41375-019-0466-0
Source DB: PubMed Journal: Leukemia ISSN: 0887-6924 Impact factor: 11.528